On October 21, 2026 Median Technologies (FR0011049824, ALMDT, "Median" or the "Company"), developer of eyonis, a suite of artificial intelligence (AI) powered Software as Medical Devices (SaMD) for early cancer detection and diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, reported that it will participate in the ESMO (Free ESMO Whitepaper) Congress 2026, taking place October 23-27, 2026, at IFEMA in Madrid, Spain.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Median’s iCRO team will welcome attendees at booth #1098, Hall 10, from October 23 to 26, from 10:00 a.m. to 6:30 p.m. (technical exhibition hours), where it will showcase the latest advances in its central imaging and AI-powered image analysis services for oncology clinical trials.
The Company will host an interactive session at its booth exploring practical insights from the implementation of RANO 2.0, the updated response assessment framework for neuro-oncology, in central imaging review:
RANO 2.0 in Central Imaging Review: Driving Success in Neuro-Oncology Trials
Sunday, October 25 | 12:00 p.m.-12:30 p.m. Presenters: Antoine Iannessi, VP Medical Affairs, iCRO, Median Technologies, and Anne-Sophie Auroux, VP Operations, iCRO, Median Technologies
The Company will also present the ePoster " Prevalence of Emphysema in Patients with Non Small Lung Cancer (NSCLC)" (2560eP).
(Press release, MEDIAN Technologies, OCT 21, 2026, View Source [SID1234673651])